NCT03904550View on ClinicalTrials.gov

Neuromuscular Blockade in Patients With Severe Renal Impairment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

July 1, 2023

Conditions

Neuromuscular BlockadeRenal Impairment

Interventions

DRUG

Cisatracurium + Neostigmine

Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate

DRUG

Rocuronium + Sugammadex

Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex

Trial Locations (1)

75390

Parkland Health & Hospital System, Dallas

All Listed Sponsors

lead

University of Texas Southwestern Medical Center

OTHER

NCT03904550 - Neuromuscular Blockade in Patients With Severe Renal Impairment | Biotech Hunter | Biotech Hunter